Pharmacokinetic aspects of retinal drug delivery

Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is appl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Progress in retinal and eye research 2017-03, Vol.57, p.134-185
Hauptverfasser: del Amo, Eva M., Rimpelä, Anna-Kaisa, Heikkinen, Emma, Kari, Otto K., Ramsay, Eva, Lajunen, Tatu, Schmitt, Mechthild, Pelkonen, Laura, Bhattacharya, Madhushree, Richardson, Dominique, Subrizi, Astrid, Turunen, Tiina, Reinisalo, Mika, Itkonen, Jaakko, Toropainen, Elisa, Casteleijn, Marco, Kidron, Heidi, Antopolsky, Maxim, Vellonen, Kati-Sisko, Ruponen, Marika, Urtti, Arto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 185
container_issue
container_start_page 134
container_title Progress in retinal and eye research
container_volume 57
creator del Amo, Eva M.
Rimpelä, Anna-Kaisa
Heikkinen, Emma
Kari, Otto K.
Ramsay, Eva
Lajunen, Tatu
Schmitt, Mechthild
Pelkonen, Laura
Bhattacharya, Madhushree
Richardson, Dominique
Subrizi, Astrid
Turunen, Tiina
Reinisalo, Mika
Itkonen, Jaakko
Toropainen, Elisa
Casteleijn, Marco
Kidron, Heidi
Antopolsky, Maxim
Vellonen, Kati-Sisko
Ruponen, Marika
Urtti, Arto
description Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.
doi_str_mv 10.1016/j.preteyeres.2016.12.001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1853742143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1350946216300635</els_id><sourcerecordid>1853742143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-2391ccf38fedb29fb09a6af93c1f3b8fb088b0d314da2889ea71f8c7706e3e2e3</originalsourceid><addsrcrecordid>eNqFkMlOwzAQhi0EoqXwCihHLgljO4tzhIpNqgQHOFuOMwaXbNhJpb49rlrgiDTSLPpnfs1HSEQhoUDz63UyOBxxiw59wsIkoSwBoEdkTkXBY5rz7DjUPIO4THM2I2ferwEghzI7JTMmIATQOYGXD-VapftP2-FodaT8gHr0UW-iYGE71US1m96jGhu7Qbc9JydGNR4vDnlB3u7vXpeP8er54Wl5s4p1WsIYM15SrQ0XBuuKlaaCUuXKlFxTwysReiEqqDlNa8WEKFEV1AhdFJAjR4Z8Qa72dwfXf03oR9lar7FpVIf95CUVGS9SRlMepGIv1a733qGRg7OtcltJQe54ybX84yV3vCRlMvwfVi8PLlPVYv27-AMoCG73Agy_biw66bXFTmNtXeAk697-7_INmL6BnA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1853742143</pqid></control><display><type>article</type><title>Pharmacokinetic aspects of retinal drug delivery</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>del Amo, Eva M. ; Rimpelä, Anna-Kaisa ; Heikkinen, Emma ; Kari, Otto K. ; Ramsay, Eva ; Lajunen, Tatu ; Schmitt, Mechthild ; Pelkonen, Laura ; Bhattacharya, Madhushree ; Richardson, Dominique ; Subrizi, Astrid ; Turunen, Tiina ; Reinisalo, Mika ; Itkonen, Jaakko ; Toropainen, Elisa ; Casteleijn, Marco ; Kidron, Heidi ; Antopolsky, Maxim ; Vellonen, Kati-Sisko ; Ruponen, Marika ; Urtti, Arto</creator><creatorcontrib>del Amo, Eva M. ; Rimpelä, Anna-Kaisa ; Heikkinen, Emma ; Kari, Otto K. ; Ramsay, Eva ; Lajunen, Tatu ; Schmitt, Mechthild ; Pelkonen, Laura ; Bhattacharya, Madhushree ; Richardson, Dominique ; Subrizi, Astrid ; Turunen, Tiina ; Reinisalo, Mika ; Itkonen, Jaakko ; Toropainen, Elisa ; Casteleijn, Marco ; Kidron, Heidi ; Antopolsky, Maxim ; Vellonen, Kati-Sisko ; Ruponen, Marika ; Urtti, Arto</creatorcontrib><description>Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</description><identifier>ISSN: 1350-9462</identifier><identifier>EISSN: 1873-1635</identifier><identifier>DOI: 10.1016/j.preteyeres.2016.12.001</identifier><identifier>PMID: 28028001</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Angiogenesis Inhibitors - administration &amp; dosage ; Angiogenesis Inhibitors - pharmacokinetics ; Animals ; Choroid ; Clearance ; Distribution ; Drug Delivery Systems ; Humans ; Intravitreal ; Intravitreal Injections ; Pharmacokinetic modeling ; Retina ; Retina - metabolism ; Retinal Diseases - drug therapy ; Retinal Diseases - metabolism ; Sub-conjunctival ; Suprachoroidal ; Tissue Distribution ; Topical ; Transport ; Vitreous</subject><ispartof>Progress in retinal and eye research, 2017-03, Vol.57, p.134-185</ispartof><rights>2017 The Authors</rights><rights>Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-2391ccf38fedb29fb09a6af93c1f3b8fb088b0d314da2889ea71f8c7706e3e2e3</citedby><cites>FETCH-LOGICAL-c490t-2391ccf38fedb29fb09a6af93c1f3b8fb088b0d314da2889ea71f8c7706e3e2e3</cites><orcidid>0000-0003-4093-3465 ; 0000-0002-1201-5010 ; 0000-0001-8549-7092 ; 0000-0002-4380-4127 ; 0000-0001-5923-7289 ; 0000-0001-6617-1513 ; 0000-0002-6090-1156 ; 0000-0003-2109-3632 ; 0000-0001-6234-9193</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1350946216300635$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28028001$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>del Amo, Eva M.</creatorcontrib><creatorcontrib>Rimpelä, Anna-Kaisa</creatorcontrib><creatorcontrib>Heikkinen, Emma</creatorcontrib><creatorcontrib>Kari, Otto K.</creatorcontrib><creatorcontrib>Ramsay, Eva</creatorcontrib><creatorcontrib>Lajunen, Tatu</creatorcontrib><creatorcontrib>Schmitt, Mechthild</creatorcontrib><creatorcontrib>Pelkonen, Laura</creatorcontrib><creatorcontrib>Bhattacharya, Madhushree</creatorcontrib><creatorcontrib>Richardson, Dominique</creatorcontrib><creatorcontrib>Subrizi, Astrid</creatorcontrib><creatorcontrib>Turunen, Tiina</creatorcontrib><creatorcontrib>Reinisalo, Mika</creatorcontrib><creatorcontrib>Itkonen, Jaakko</creatorcontrib><creatorcontrib>Toropainen, Elisa</creatorcontrib><creatorcontrib>Casteleijn, Marco</creatorcontrib><creatorcontrib>Kidron, Heidi</creatorcontrib><creatorcontrib>Antopolsky, Maxim</creatorcontrib><creatorcontrib>Vellonen, Kati-Sisko</creatorcontrib><creatorcontrib>Ruponen, Marika</creatorcontrib><creatorcontrib>Urtti, Arto</creatorcontrib><title>Pharmacokinetic aspects of retinal drug delivery</title><title>Progress in retinal and eye research</title><addtitle>Prog Retin Eye Res</addtitle><description>Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</description><subject>Angiogenesis Inhibitors - administration &amp; dosage</subject><subject>Angiogenesis Inhibitors - pharmacokinetics</subject><subject>Animals</subject><subject>Choroid</subject><subject>Clearance</subject><subject>Distribution</subject><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>Intravitreal</subject><subject>Intravitreal Injections</subject><subject>Pharmacokinetic modeling</subject><subject>Retina</subject><subject>Retina - metabolism</subject><subject>Retinal Diseases - drug therapy</subject><subject>Retinal Diseases - metabolism</subject><subject>Sub-conjunctival</subject><subject>Suprachoroidal</subject><subject>Tissue Distribution</subject><subject>Topical</subject><subject>Transport</subject><subject>Vitreous</subject><issn>1350-9462</issn><issn>1873-1635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMlOwzAQhi0EoqXwCihHLgljO4tzhIpNqgQHOFuOMwaXbNhJpb49rlrgiDTSLPpnfs1HSEQhoUDz63UyOBxxiw59wsIkoSwBoEdkTkXBY5rz7DjUPIO4THM2I2ferwEghzI7JTMmIATQOYGXD-VapftP2-FodaT8gHr0UW-iYGE71US1m96jGhu7Qbc9JydGNR4vDnlB3u7vXpeP8er54Wl5s4p1WsIYM15SrQ0XBuuKlaaCUuXKlFxTwysReiEqqDlNa8WEKFEV1AhdFJAjR4Z8Qa72dwfXf03oR9lar7FpVIf95CUVGS9SRlMepGIv1a733qGRg7OtcltJQe54ybX84yV3vCRlMvwfVi8PLlPVYv27-AMoCG73Agy_biw66bXFTmNtXeAk697-7_INmL6BnA</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>del Amo, Eva M.</creator><creator>Rimpelä, Anna-Kaisa</creator><creator>Heikkinen, Emma</creator><creator>Kari, Otto K.</creator><creator>Ramsay, Eva</creator><creator>Lajunen, Tatu</creator><creator>Schmitt, Mechthild</creator><creator>Pelkonen, Laura</creator><creator>Bhattacharya, Madhushree</creator><creator>Richardson, Dominique</creator><creator>Subrizi, Astrid</creator><creator>Turunen, Tiina</creator><creator>Reinisalo, Mika</creator><creator>Itkonen, Jaakko</creator><creator>Toropainen, Elisa</creator><creator>Casteleijn, Marco</creator><creator>Kidron, Heidi</creator><creator>Antopolsky, Maxim</creator><creator>Vellonen, Kati-Sisko</creator><creator>Ruponen, Marika</creator><creator>Urtti, Arto</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4093-3465</orcidid><orcidid>https://orcid.org/0000-0002-1201-5010</orcidid><orcidid>https://orcid.org/0000-0001-8549-7092</orcidid><orcidid>https://orcid.org/0000-0002-4380-4127</orcidid><orcidid>https://orcid.org/0000-0001-5923-7289</orcidid><orcidid>https://orcid.org/0000-0001-6617-1513</orcidid><orcidid>https://orcid.org/0000-0002-6090-1156</orcidid><orcidid>https://orcid.org/0000-0003-2109-3632</orcidid><orcidid>https://orcid.org/0000-0001-6234-9193</orcidid></search><sort><creationdate>201703</creationdate><title>Pharmacokinetic aspects of retinal drug delivery</title><author>del Amo, Eva M. ; Rimpelä, Anna-Kaisa ; Heikkinen, Emma ; Kari, Otto K. ; Ramsay, Eva ; Lajunen, Tatu ; Schmitt, Mechthild ; Pelkonen, Laura ; Bhattacharya, Madhushree ; Richardson, Dominique ; Subrizi, Astrid ; Turunen, Tiina ; Reinisalo, Mika ; Itkonen, Jaakko ; Toropainen, Elisa ; Casteleijn, Marco ; Kidron, Heidi ; Antopolsky, Maxim ; Vellonen, Kati-Sisko ; Ruponen, Marika ; Urtti, Arto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-2391ccf38fedb29fb09a6af93c1f3b8fb088b0d314da2889ea71f8c7706e3e2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Angiogenesis Inhibitors - administration &amp; dosage</topic><topic>Angiogenesis Inhibitors - pharmacokinetics</topic><topic>Animals</topic><topic>Choroid</topic><topic>Clearance</topic><topic>Distribution</topic><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>Intravitreal</topic><topic>Intravitreal Injections</topic><topic>Pharmacokinetic modeling</topic><topic>Retina</topic><topic>Retina - metabolism</topic><topic>Retinal Diseases - drug therapy</topic><topic>Retinal Diseases - metabolism</topic><topic>Sub-conjunctival</topic><topic>Suprachoroidal</topic><topic>Tissue Distribution</topic><topic>Topical</topic><topic>Transport</topic><topic>Vitreous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>del Amo, Eva M.</creatorcontrib><creatorcontrib>Rimpelä, Anna-Kaisa</creatorcontrib><creatorcontrib>Heikkinen, Emma</creatorcontrib><creatorcontrib>Kari, Otto K.</creatorcontrib><creatorcontrib>Ramsay, Eva</creatorcontrib><creatorcontrib>Lajunen, Tatu</creatorcontrib><creatorcontrib>Schmitt, Mechthild</creatorcontrib><creatorcontrib>Pelkonen, Laura</creatorcontrib><creatorcontrib>Bhattacharya, Madhushree</creatorcontrib><creatorcontrib>Richardson, Dominique</creatorcontrib><creatorcontrib>Subrizi, Astrid</creatorcontrib><creatorcontrib>Turunen, Tiina</creatorcontrib><creatorcontrib>Reinisalo, Mika</creatorcontrib><creatorcontrib>Itkonen, Jaakko</creatorcontrib><creatorcontrib>Toropainen, Elisa</creatorcontrib><creatorcontrib>Casteleijn, Marco</creatorcontrib><creatorcontrib>Kidron, Heidi</creatorcontrib><creatorcontrib>Antopolsky, Maxim</creatorcontrib><creatorcontrib>Vellonen, Kati-Sisko</creatorcontrib><creatorcontrib>Ruponen, Marika</creatorcontrib><creatorcontrib>Urtti, Arto</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in retinal and eye research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>del Amo, Eva M.</au><au>Rimpelä, Anna-Kaisa</au><au>Heikkinen, Emma</au><au>Kari, Otto K.</au><au>Ramsay, Eva</au><au>Lajunen, Tatu</au><au>Schmitt, Mechthild</au><au>Pelkonen, Laura</au><au>Bhattacharya, Madhushree</au><au>Richardson, Dominique</au><au>Subrizi, Astrid</au><au>Turunen, Tiina</au><au>Reinisalo, Mika</au><au>Itkonen, Jaakko</au><au>Toropainen, Elisa</au><au>Casteleijn, Marco</au><au>Kidron, Heidi</au><au>Antopolsky, Maxim</au><au>Vellonen, Kati-Sisko</au><au>Ruponen, Marika</au><au>Urtti, Arto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic aspects of retinal drug delivery</atitle><jtitle>Progress in retinal and eye research</jtitle><addtitle>Prog Retin Eye Res</addtitle><date>2017-03</date><risdate>2017</risdate><volume>57</volume><spage>134</spage><epage>185</epage><pages>134-185</pages><issn>1350-9462</issn><eissn>1873-1635</eissn><abstract>Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28028001</pmid><doi>10.1016/j.preteyeres.2016.12.001</doi><tpages>52</tpages><orcidid>https://orcid.org/0000-0003-4093-3465</orcidid><orcidid>https://orcid.org/0000-0002-1201-5010</orcidid><orcidid>https://orcid.org/0000-0001-8549-7092</orcidid><orcidid>https://orcid.org/0000-0002-4380-4127</orcidid><orcidid>https://orcid.org/0000-0001-5923-7289</orcidid><orcidid>https://orcid.org/0000-0001-6617-1513</orcidid><orcidid>https://orcid.org/0000-0002-6090-1156</orcidid><orcidid>https://orcid.org/0000-0003-2109-3632</orcidid><orcidid>https://orcid.org/0000-0001-6234-9193</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1350-9462
ispartof Progress in retinal and eye research, 2017-03, Vol.57, p.134-185
issn 1350-9462
1873-1635
language eng
recordid cdi_proquest_miscellaneous_1853742143
source MEDLINE; Elsevier ScienceDirect Journals
subjects Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - pharmacokinetics
Animals
Choroid
Clearance
Distribution
Drug Delivery Systems
Humans
Intravitreal
Intravitreal Injections
Pharmacokinetic modeling
Retina
Retina - metabolism
Retinal Diseases - drug therapy
Retinal Diseases - metabolism
Sub-conjunctival
Suprachoroidal
Tissue Distribution
Topical
Transport
Vitreous
title Pharmacokinetic aspects of retinal drug delivery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A43%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20aspects%20of%20retinal%20drug%20delivery&rft.jtitle=Progress%20in%20retinal%20and%20eye%20research&rft.au=del%20Amo,%20Eva%20M.&rft.date=2017-03&rft.volume=57&rft.spage=134&rft.epage=185&rft.pages=134-185&rft.issn=1350-9462&rft.eissn=1873-1635&rft_id=info:doi/10.1016/j.preteyeres.2016.12.001&rft_dat=%3Cproquest_cross%3E1853742143%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1853742143&rft_id=info:pmid/28028001&rft_els_id=S1350946216300635&rfr_iscdi=true